Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7009816 | 0.94 | MMP1 (0.41) | MMP1MMP9MMP13ADAM17NR3C1 | |
| SCHEMBL6290539 | 0.91 | NR3C1 (0.51) | MMP1MMP9MMP13ADAM17NR3C1 | |
| SCHEMBL6289450 | 0.87 | MMP1 (0.48) | MMP1MMP9MMP13ADAM17NR3C1 | |
| SCHEMBL7010019 | 0.85 | MMP13 (0.39) | MMP1MMP9MMP13ADAM17NR3C1 | |
| SCHEMBL7010518 | 0.81 | PTGDR2 (0.41) | MMP1MMP9MMP13ADAM17NR3C1 | |
| SCHEMBL7010479 | 0.79 | PTGDR2 (0.43) | MMP1MMP9MMP13ADAM17PDE4B | |
| SCHEMBL7014456 | 0.79 | MMP9 (0.40) | MMP1MMP9MMP13ADAM17NR3C1 | |
| SCHEMBL6289977 | 0.79 | GAA (0.49) | MMP1MMP9MMP13ADAM17NR3C1 | |
| SCHEMBL6289420 | 0.79 | MMP1 (0.49) | MMP1MMP9MMP13ADAM17NR3C1 | |
| SCHEMBL6293269 | 0.79 | MMP13 (0.47) | MMP1MMP9MMP13ADAM17PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021413-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | WYETH CORP (US) | 2003-06-11 | — | — | EP | claimed |
| US-6548524-B2 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | claimed |
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2002-09-19 | — | — | US | claimed |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION | 2001-11-29 | — | — | US | claimed |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2001-09-27 | — | — | US | claimed |
| EP-1021413-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | WYETH CORP (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6548524-B2 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6534491-B2 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-6498167-B2 | NITROGEN CONTAINING BICYCLIC HETEROAROMATIC COMPOUND CONTAINING SULFONAMIDE AND HYDROXYAMIDE GROUPS, USEFUL IN TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, BONE DISEASE AND HIV INFECTIONS | AMERICAN CYANAMID COMPANY | 2002-12-24 | — | — | US | disclosed |
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2002-09-19 | — | — | US | disclosed |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION | 2001-11-29 | — | — | US | disclosed |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6228869-B1 | ANTITUMOR, ANTIMETASTASIS, ANTIARTHRITIC, AND WOUND HEALING AGENTS; QUINOLINE AND ISOQUINOLINE DERIVATIVES | AMERICAN CYANAMID COMPANY | 2001-05-08 | — | — | US | disclosed |
| EP-1021413-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998016514-A1 | ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, OGFR | MMP1 50/4885MMP9 33/4885MMP13 30/4885 |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, TGFBR2 | MMP1 40/4885MMP9 21/4885MMP13 36/4885 |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | MSR1, TIMP3, TGFBR2 | MMP1 51/4885MMP9 26/4885MMP13 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.